Navigation Links
Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Date:1/13/2009

HOPKINTON, Mass., Jan. 13 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced that on January 8, 2009 it entered into a securities purchase agreement (the "Agreement") with Robert Gipson for the private placement of 1,000,000 shares of common stock of the Company at a purchase price of $1.00 per share. The financing resulted in total gross proceeds of $1 million. In connection with the Agreement, Mr. Gipson agreed to the cancellation of a warrant previously issued to him to purchase 543,478 shares of common stock of the Company at a purchase price of $1.84 per share. The Company intends to use the net proceeds from this private placement to fund its research and development programs and otherwise for general corporate purposes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )

In connection with the Agreement, the Company issued an additional 456,522 shares of its common stock to Mr. Gipson pursuant to a Letter Agreement (the "Letter Agreement") between the Company and Mr. Gipson dated November 20, 2008. The Letter Agreement provided that if the Company sold shares of its common stock at a price below $1.84, subject to certain exceptions, prior to December 31, 2009, Mr. Gipson would be entitled to receive, for no additional consideration, additional shares of common stock and warrants in accordance with a pre-determined formula. Under the Agreement, Mr. Gipson has waived his right to additional warrants.

The securities offered and sold by Alseres in this private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from registration requirements. Alseres has agreed to file a registration statement with the SEC covering resale of the shares of common stock and the shares of common stock issuable upon exercise of the warrants issued in the private placement.

This notice is issued pursuant to Rule 135c under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the Company's ability to obtain financing, the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

Alseres, Cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc.

    Contact:

    Ken Rice -- 508-497-2360 ext. 226
    Alseres Pharmaceuticals, Inc.
    krice@alseres.com

http://www.alseres.com/


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
2. Alseres Pharmaceuticals, Inc. Raises $5 Million
3. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
4. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
5. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
6. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
7. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
8. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
9. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
10. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
11. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2016)... ... 2016 , ... Doctors in Rome say micronutrients found in certain foods have ... Mesothelioma has just posted an article on the new research. Click here to ... Sciences and Translational Medicine evaluated more than 150 studies on polyphenols in cancer for ...
(Date:5/20/2016)... NC (PRWEB) , ... May 20, 2016 , ... Korean ... suggesting that it may offer a new way to treat the disease. Surviving Mesothelioma ... it now. , Scientists from several Korean institutions based their mesothelioma study on ...
(Date:5/19/2016)... British Columbia , May 19, 2016 /PRNewswire/ ... Global Innovations Inc. (AGI), based out of ... added Greenlane Biogas Ltd. to its existing portfolio ... contract manufacturing agreement. AFS along with its sister ... (ABT) is a vertically integrated industrial group that ...
(Date:5/19/2016)... DIEGO , May 19, 2016 ... (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today ... creating the first cord blood based cancer immunotherapeutic ... provisional patent application, Regen described a generation of ... was potentiated by gene silencing.  The product in ...
Breaking Biology Technology:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
Breaking Biology News(10 mins):